Other Events ·
enGene Therapeutics Inc. amended its previous 8-K to update restructuring costs following a 50% workforce reduction
ENGNenGene Therapeutics Inc.
enGene Therapeutics Inc. amended its previous 8-K to update restructuring costs following a 50% workforce reduction. The company approved performance-based equity retention awards for employees, including CEO Ronald Cooper, which vest upon FDA BLA filing acceptance and detalimogene regulatory approval by late 2027 and 2028 respectively. Total estimated restructuring costs include $5.7 to $6.4 million in cash and up to $4.7 to $5.0 million in non-cash stock-based compensation. enGene Therapeutics Inc. is a biotechnology company developing gene therapies.